Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--NantWorks, LLC, and ImmunityBio, Inc. (NASDAQ: IBRX), today announced the inaugural U.S.-Saudi Biotech Alliance Summit, to be held in conjunction with the 44th An
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
11:15am, Monday, 29'th Dec 2025
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
09:00am, Monday, 29'th Dec 2025
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of
Reviewing HCW Biologics (NASDAQ:HCWB) and ImmunityBio (NASDAQ:IBRX)
01:14am, Tuesday, 23'rd Dec 2025
HCW Biologics (NASDAQ: HCWB - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based o
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
11:40am, Thursday, 18'th Dec 2025
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calm
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy
12:00pm, Friday, 12'th Dec 2025
The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillu
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing a
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs
05:00am, Wednesday, 03'rd Dec 2025
ImmunityBio delivered strong 3Q25 results, with Anktiva driving 434% YoY product revenue growth and a narrowed operating loss. IBRX's cash position improved to $257.8 million, providing a 3-4 quarter
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know
12:29pm, Wednesday, 19'th Nov 2025
Bought 6,565,709 shares of ImmunityBio, an increase of $16.15 million in position value This new position ranks as the fund's 2nd-largest holding, representing 4.4% of AUM
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech
04:56am, Wednesday, 19'th Nov 2025
ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech
04:56am, Wednesday, 19'th Nov 2025
ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
09:00am, Thursday, 13'th Nov 2025
CULVER CITY, Calif.--(BUSINESS WIRE)--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder canc
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30
Chicago Partners Investment Group LLC Invests $70,000 in ImmunityBio, Inc. $IBRX
04:08am, Sunday, 26'th Oct 2025
Chicago Partners Investment Group LLC purchased a new stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) in the second quarter, according to its most recent disclosure with the Securities and Exchang
